Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 12/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12338468 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL25713917 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL19656107 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL16939967 | 0.86 | CDA (0.76) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL23227176 | 0.81 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL171923 | 0.81 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL13895215 | 0.81 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL20788791 | 0.81 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL23467212 | 0.81 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 | |
| Cedazuridine SCHEMBL25286013 | 0.80 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2025-01-02 | — | — | US | claimed |
| WO-2023069529-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2023-04-27 | — | — | WO | claimed |
| US-20230122664-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | CUSTOMERS BANK | 2023-04-20 | — | — | US | claimed |
| US-20230055298-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | ADIMABIO LLC | 2023-02-23 | — | — | US | claimed |
| WO-2021211890-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | ADIMABIO LLC (US) | 2021-10-21 | — | — | WO | claimed |
| EP-4704834-A1 | RESPONSE-BASED DOSING FOR TREATING CANCER WITH A HYPOMETHYLATING AGENT AND CEDAZURIDINE | Taiho Pharmaceutical Co., Ltd. (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-20250177427-A1 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-06-05 | — | — | US | disclosed |
| US-12239653-B2 | Combination decitabine and cedazuridine solid oral dosage forms | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20250000888-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH DECITABINE AND CEDAZURIDINE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-02 | — | — | US | disclosed |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2025-01-02 | — | — | US | disclosed |
| EP-4470622-A2 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024229073-A1 | RESPONSE-BASED DOSING FOR TREATING CANCER WITH A HYPOMETHYLATING AGENT AND CEDAZURIDINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | WO | disclosed |
| WO-2023049731-A2 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH DECITABINE AND CEDAZURIDINE | OTSUKA PHARMACEUTICAL CO., LTD. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230089147-A1 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| US-20230055298-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | ADIMABIO LLC | 2023-02-23 | — | — | US | disclosed |
| US-20220110958-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-04-14 | — | — | US | disclosed |
| US-11224610-B2 | Low dose combination CDA substrate drug/cedazuridine with extended administration | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-18 | — | — | US | disclosed |
| WO-2021211890-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | ADIMABIO LLC (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20200085848-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
| US-20190076464-A1 | CYTIDINE DEAMINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER | INSERM OMSTOTIT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE (FR) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11224610-B2 | Low dose combination CDA substrate drug/cedazuridine with extended administration | CDA, DNMT1, DUT | CDA 1/4885PDE4D 2182/4885PDE3A 2945/4885 |
| US-20230122664-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | CDA 4/4885PDE4D 637/4885PDE3A 572/4885 |
| US-20250177427-A1 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | DNMT3A, DNMT1, CDA | CDA 3/4885PDE4D 464/4885PDE3A 613/4885 |
| US-12239653-B2 | Combination decitabine and cedazuridine solid oral dosage forms | DNMT3A, DNMT1, CDA | CDA 3/4885PDE4D 464/4885PDE3A 613/4885 |
| US-20250000888-A1 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH DECITABINE AND CEDAZURIDINE | CDA, DNMT1, TP53 | CDA 1/4885PDE4D 1987/4885PDE3A 2418/4885 |
| US-20200085848-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | CDA, DNMT1, DUT | CDA 1/4885PDE4D 2182/4885PDE3A 2945/4885 |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | CDA 4/4885PDE4D 637/4885PDE3A 572/4885 |
| US-20220110958-A1 | LOW DOSE COMBINATION CDA SUBSTRATE DRUG/CEDAZURIDINE WITH EXTENDED ADMINISTRATION | CDA, DNMT1, DUT | CDA 1/4885PDE4D 2182/4885PDE3A 2945/4885 |
| US-20230055298-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | CDA 4/4885PDE4D 637/4885PDE3A 572/4885 |
| US-20230089147-A1 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | DNMT3A, DNMT1, CDA | CDA 3/4885PDE4D 464/4885PDE3A 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.